PARIS (dpa-AFX) - Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study. The data was published in The Lancet Infectious Diseases.
'This universal RSV immunization program with Beyfortus showed decreased RSV-related hospitalizations and outpatient illness burden during the first season, with persistent impact seen on RSV hospitalizations through the second season,' said Federico Martinón-Torres, Head of Pediatrics at Santiago University Hospital in Spain, and principal investigator of the NIRSE-GAL study.
At last close, shares of Sanofi were trading at 77.62 euros.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
